Hepatitis C Treatment Snapshots: Daclatasvir

Hepatitis C Treatment Snapshots: Daclatasvir

For a simplified snapshot from TREAT Asia/amfAR on daclatasvir, a second generation direct-acting antiviral for the treatment of hepatitis C, please click here.

/ News

Share the Post

Related Posts

IAC a community group in Indonesia demanding national food and drugs authority to expedite registration process of DAA medicines in Indonesia
Four Indian generic companies take sub license from MPP on daclatasvir
New WHO guideline on care and treatment of chronic hepatitis C
Asia-Pacific Aids Groups Express Deep Dismay At Conclusion Of Secretly Negotiated Trans-Pacific Partnership Agreement That Threatens Future Access To Affordable Generic Medicines And Sustainable Development Goals
Factsheet on updated WHO guidelines for the screening, care and treatment of persons with hepatitis C infection from TREAT Asia/amfAR
Pricing and availability of generic Indian Ledipasvir and Sofosbuvir co-formulation as on 26 April 2016
The use of generic DAAs for hepatitis C treatment, Freeman et al 2016
Flawed patents on hepatitis C drugs latest to be challenged in global push for access